Síndrome cardiorrenal: diagnóstico y tratamiento / Cardiorenal syndrome: diagnosis and treatment

Introducción: Las enfermedades cardíacas y renales coexisten con frecuencia. El síndrome cardiorrenal es una entidad compleja; en ella, la disfunción primaria cardíaca produce daño renal (tipos 1 y 2) y viceversa (tipos 3 y 4) o efecto de una enfermedad sistémica que afecta a ambos órganos (tipo 5). Objetivo: Actualizar el diagnóstico y tratamiento de los pacientes con síndrome cardiorrenal. Métodos: Se utilizan métodos teóricos y empíricos para realizar análisis del conocimiento actualizado sobre el tema. Se ha definido la existencia de un síndrome cardiorrenal que compromete a ambos órganos, con interacción bidireccional. En su detección, el diagnóstico clínico es insuficiente y requiere marcadores bioquímicos; estas herramientas, junto con la medición del sodio urinario, permite vigilar la efectividad terapéutica. Otro recurso es la ultrafiltración, según complicaciones. Conclusiones: Se debe indicar tratamiento con base en la evidencia para mejorar la calidad de vida, reducir la mortalidad y retrasar el deterioro de la función renal y cardíaca a largo plazo; el trasplante renal se debe considerar en pacientes en diálisis con disfunción ventricular severa. Idealmente, deberían recibir un trasplante combinado: cardíaco y renal, lo cual es difícil; algunos pacientes sometidos exclusivamente a trasplante renal presentan una mejoría notable en su fracción de eyección y en la sobrevida.

Introduction: heart and kidney diseases frequently coexist. Cardiorenal syndrome is a complex entity in which primary cardiac dysfunction causes a kidney damage (types 1 and 2) and vice versa (types 3 and 4) or an effect of a systemic disease that affects both organs (type 5). Objective: to update the diagnosis and treatment of patients with cardiorenal syndrome. Methods: theoretical and empirical methods are used to carry out the analysis of updated knowledge on the subject. The existence of a cardiorenal syndrome that compromises both organs has been defined with bidirectional interaction. In its detection, clinical diagnosis is insufficient and requires biochemical markers; these tools, together with the measurement of urinary sodium, allow us to monitor therapeutic effectiveness. Another resource is ultrafiltration, according to complications. Conclusions: evidence-based treatment should be indicated to improve quality of life, reduce mortality, and delay the deterioration of renal and cardiac function in the long term; kidney transplantation should be considered in dialysis patients with severe ventricular dysfunction. Ideally, they should receive a combined transplant: heart and kidney, which is difficult; some patients undergoing exclusively a renal transplantation show a notable improvement in their ejection fraction and survival.

Role of complement activation in the pathogenesis of severe cardiorenal injury in patients with primary malignant hypertension / 中华肾脏病杂志

Objective:To investigate the role of complement activation in the pathogenesis of primary malignant hypertension (MHT) with nephrosclerosis complicated with severe cardiorenal injury.Methods:Data of MHT patients with nephrosclerosis proven by biopsy from January 2010 to December 2020 in the Beijing Anzhen Hospital, Capital Medical University were retrospectively analyzed. The expressions of complement-related component C4d, C1q, complement factor H-related protein 5, C3c and C5b-9 were detected by immunohistochemical staining. According to whether the patients were complicated with acute heart failure (AHF) and/or acute kidney injury (AKI), they were divided into severe cardiorenal injury group and non-severe cardiorenal injury group. The differences of clinicopathological data between the two groups were compared. According to the degree of C4d deposition in renal tissues, patients were divided into C4d diffused deposition group and non-C4d diffused deposition group. The severity of cardiorenal injury and the pathological characteristics of thrombotic microangiopathy in renal tissues were compared between the two groups.Results:A total of 33 patients were enrolled in this study, of which 17 cases (51.5%) were complicated with severe cardiorenal injury; AHF occurred in 16 patients (48.5%), AKI occurred in 8 patients (26.7%), and AHF and AKI were combined in 7 patients (21.2%). Compared with non-severe cardiorenal injury group, patients in severe cardiorenal injury group had higher levels of baseline lactate dehydrogenase [326.0 (217.0, 366.0) IU/L vs 197.0 (165.0, 220.0) IU/L, Z=37.000, P=0.002] and hemoglobin [(143.6±24.0) g/L vs (106.4±24.7) g/L, t=38.500, P<0.001], lower levels of 12 h urinary incontinence osmolality [400.0 (342.5, 504.0) mmol/L vs 476.0 (432.3, 616.5) mmol/L, Z=72.000, P=0.021] and serum albumin [(36.2±9.4) g/L vs (43.2±6.2) g/L, t=6.423, P=0.017], and thicker left ventricular posterior wall [(14.0±2.1) mm vs (12.1±1.1) mm, t=6.552, P=0.018]. The immunohistochemical results of kidney tissue showed that the proportions of C4d and C5b-9 diffused deposition in severe cardiorenal injury group were significantly higher than those in non-severe cardiorenal injury group (5/16 vs 0/15, P=0.043; 12/16 vs 5/15, P=0.032). Compared with non-C4d diffused deposition group, C4d diffused deposition group had higher incidence of AHF (5/5 vs 10/26, P=0.018), poorer heart function, more severe ventricular remodeling, and shorter history of hypertension [2.0 (0, 12.0) months vs 48.0 (9.5, 84.0) months, Z=22.500, P=0.022]. Conclusions:The incidence of severe cardiorenal injury in MHT patients with nephrosclerosis is about 51.5%. The proportion of diffuse deposition of complement activated components in renal tissues in patients with severe cardiorenal injury is higher than that in patients with non-severe cardiorenal injury. Overactivation of complement may be involved in the pathogenic process of severe heart and kidney injury caused by MHT.

Early mortality risk prediction models for patients with sepsis-induced cardiorenal syndrome based on machine learning / 中华肾脏病杂志

Objective:To explore the method of constructing an early mortality risk prediction model for patients with sepsis-induced cardiorenal syndrome by machine learning algorithm, so as to provide a basis for early clinical identification of high-risk patients and accurate treatment.Methods:Patients with sepsis-induced cardiorenal syndrome from January 1, 2015 to May 31, 2019 in Tongji Hospital, Tongji University were enrolled. Basic characteristics, laboratory indexes, hospitality treatment and other relevant baseline data were collected. Thirty-day mortality was defined as the primary end-point event after the enrolled patients were diagnosed. Python software was applied to establish different machine learning models, and the area under the receiver -operating characteristic curve ( AUC) was used to evaluate the predictive value of models. Disease-related risk factors were selected according to the most optimal model. Importantly, visualized decision tree and semi-naive Bayesian (sNB) models were established to further explore the interrelationship between these risk factors. Results:A total of 340 patients were included, of whom 114 patients (33.5%) died within 30 days after diagnosis. The AUC of support vector machine (SVM), random forest (RF), gradient boosting decision tree (GBDT), extreme gradient boosting (XGBoost), and light gradient boosting machine (LGBM) prediction models were 0.652, 0.868, 0.870, 0.754, and 0.852, respectively. The AUC of GBDT model had the most efficiency to predict end-point events, and the prediction AUC value was better. According to the feature ranking of GBDT model, the relevant influencing factors were selected, including total sequential organ failure assessment (SOFA) score, neural SOFA score, vasoactive drug application, cardiac troponin I (cTNI), age, myoglobin, circulation system SOFA score, chronic kidney disease, heart rate and baseline serum creatinine. Visualized decision tree model had 4 layers, 15 nodes and 8 terminal nodes as evidenced by total SOFA score, myoglobin, baseline serum creatinine and age. The total SOFA score, change rate of myoglobin, serum creatinine and age were included into the visualized decision model. The AUC value of the model for predicting end-point event was 0.690. sNB model revealed complex correlation between the risk factors, in which neural SOFA score was related to total SOFA score, vasoactive drug application was related to total SOFA score, and cTNI was related to baseline serum creatinine. Conclusions:A risk prediction model for patients with sepsis-induced cardiorenal syndrome is established and the model showes that high SOFA score remains the primary risk factor for patients with sepsis-induced cardiorenal syndrome based machine learning. Visualized decision tree and sNB models help clinicians to further identify the dependence and logic relationship among these risk factors clearly and provide a novel method to predict mortality risk for patients with sepsis-induced cardiorenal syndrome.

Síndrome cardiorrenal tipo 1 em região de baixo desenvolvimento: comparação entre os critérios akin e kdigo, necessidade de diálise e mortalidade / Type 1 cardiorenal syndrome in decompensated heart failure patients in a low-income region in brazil: incidence of acute kidney injury (akin and kdigo criteria), need for dialysis and mortality

Resumo Fundamento: A síndrome cardiorrenal tipo 1 associa-se a maior mortalidade em pacientes com insuficiência cardíaca (IC). No entanto, há escassez de publicações comparando critérios diagnósticos de lesão renal aguda (LRA). Objetivos: Analisar o perfil clinicofuncional de pacientes com IC e fatores associados a ocorrência de lesão renal aguda (LRA). Métodos: Estudo de coorte retrospectivo, em hospital terciário de região com baixo desenvolvimento econômico que incluiu pacientes com IC descompensada ou infarto agudo do miocárdio (IAM) recente, sendo avaliadas características clínicas, laboratoriais e ecocardiográficas comparativamente em pacientes com e sem LRA classificada pelos critérios Acute Kidney Network (AKIN) e Kidney Disease: Improving Global Outcomes (KDIGO). Nível de significância estatística com valor de p < 0,05. Resultados: Entre 81 pacientes, 61,73% evoluíram com LRA. A média de creatinina foi 1,79±1,0 mg/dL e de ureia 81,5±46,0 mg/dL, sendo maior no grupo com LRA (p < 0,05). Não foi evidenciada relação entre alterações cardíacas e redução da função renal. A doença renal crônica se associou a maior ocorrência de LRA (38% x 3,23% sem LRA, p = 0,001). Não houve diferença do KDIGO com relação ao critério AKIN. Os pacientes que desenvolveram LRA apresentaram maior mortalidade (32% x 9,8% no grupo sem LRA, p = 0,04, com odds ratio (OR) de 8,187 e intervalo de confiança 1,402-17,190, p = 0,020). Conclusão: Nessa casuística de pacientes com IC, a ocorrência de LRA foi elevada e foi fator de risco independente de mortalidade. As alterações cardíacas não se associaram à ocorrência de LRA, e os critérios diagnósticos KDIGO e AKIN apresentaram performance similar.

Abstract Background: Type 1 cardiorenal syndrome is associated with higher mortality in heart failure patients. However, few studies have compared the diagnostic criteria of acute kidney injury (AKI) in this population. Objective: To assess clinical and functional features and factors associated AKI in patients with heart failure. Method: Retrospective, cohort study on patients with decompensated heart failure or recent acute myocardial infarction, conducted in a tertiary hospital in a low-income region of Brazil. Clinical, laboratory and echocardiographic features were compared between patients with and without AKI according to the Acute Kidney Network (AKIN) and Kidney Disease: Improving Global Outcomes (KDIGO) criteria. The level of statistical significance was set at p < 0.05. Results: Of 81 patients, 61.73% had AKI. Mean creatinine and urea levels were 1.79±1.0 mg/dL and 81.5±46.0 mg/dL, respectively, and higher in the group with AKI (p < 0.05). No evidence of a relationship between cardiac changes and reduced renal function. Chronic renal disease was associated with higher prevalence of AKI. Higher mortality was observed in patients with AKI than in patients without AKI (32.0% vs. 9.8%, p = 0.04, OR 8.187 ad 95% confidence interval 1.402-17.190, p = 0.020). Conclusion: In this population of patients with heart failure, AKI was highly prevalent and considered an independent risk factor for mortality. Cardiac changes were not associated with AKI, and the KDIGO and AKIN criteria showed similar performance.

Agudización del síndrome cardiorrenal V en un paciente con COVID-19 / Worsening of cardiorenal syndrome V in a patient with COVID-19

RESUMEN Durante el mes de diciembre de 2019 en Wuhan, China, se detectaron un número de pacientes con enfermedad respiratoria aguda de origen no conocido con evolución desfavorable, identificándose el coronavirus SARS-CoV-2 como agente causal, más conocido por causar enfermedades respiratorias agudas, con neumonía intersticial y alveolar, con afectación a múltiples órganos y sistemas (sistema cardiovascular, tracto gastrointestinal, sistema hematológico, sistema nervioso y riñones). La intervención con terapias de remplazo renal en la lesión renal aguda grado III, o en la enfermedad renal crónica grado IV o V es frecuente en estos enfermos como parte del tratamiento establecido en los protocolos. Se presentó la evolución de un paciente con antecedentes de: diabetes mellitus 2, hipertensión arterial, insuficiencia cardíaca y enfermedad renal crónica, aspectos que desencadenaron un síndrome cardiorrenal V, el cual se agudizó con la exposición al virus SARS-CoV-2; fue tratado con hemodiálisis convencional.

ABSTRACT During the month of December 2019 in Wuhan, China, a number of patients with acute respiratory disease of unknown origin with unfavorable evolution were detected, identifying the SARS-CoV-2 coronavirus as the causal agent, better known for causing acute respiratory diseases, with interstitial and alveolar pneumonia, affecting multiple organs and systems (cardiovascular system, gastrointestinal tract, hematological system, nervous system and kidneys). Intervention with renal replacement therapies in grade III acute kidney injury, or in grade IV or V chronic kidney disease is frequent in these patients as part of the treatment established in the protocols. The evolution of a male patient with antecedents of type 2 diabetes mellitus, arterial hypertension, heart failure and chronic kidney disease was presented, aspects that triggered a cardiorenal syndrome V, which worsened with exposure to the SARS-CoV-2 virus; he was treated with conventional hemodialysis.

Fatores associados à síndrome cardiorrenal em pacientes com insuficiência cardíaca descompensada / Factores asociados al síndrome cardiorrenal en pacientes con insuficiencia cardíaca descompensada / Factors associated with cardiorenal syndrome in patients with decompensated heart failure

Resumo Objetivo: Identificar a prevalência da síndrome cardiorrenal (SCR) em pacientes com insuficiência cardíaca (IC) crônica descompensada e sua associação com os dados sociodemográficos, clínicos, achados admissionais, mortalidade e tempo de hospitalização. Método: Estudo transversal, com abordagem quantitativa. A amostra foi constituída por 379 prontuários de pacientes adultos com o diagnóstico médico de IC crônica descompensada, admitidos em hospital público no estado de São Paulo, ao longo de 2015. A coleta de dados ocorreu em 2016. A disfunção renal foi considerada em pacientes com diagnóstico prévio de doença renal crônica (DRC) pela taxa de filtração glomerular (TFG) < 89 mL/min/1.73 m2. Testes com valor de p menor ou igual a 0,05 foram estatisticamente significativos. Resultados: A prevalência da SCR foi de 54,1%, sendo 24,8% do tipo 1 e 29,3% do tipo 2. Os principais fatores associados à SCR foram: maior média de idade, mulheres, IC de etiologia isquêmica, menor fração de ejeção, portadores de diabetes mellitus, doença arterial coronariana, uso de estimuladores cardíacos artificiais, hipotireoidismo e doença de Chagas, bem como o perfil hemodinâmico de descompensação da IC nos tipos C e L. Destacam-se, ainda, inapetência, sonolência, estertores na ausculta respiratória, alteração na perfusão tissular, redução do débito urinário, com aumento dos níveis séricos de potássio, ureia e creatinina na avaliação clínica inicial. Os pacientes com disfunção renal apresentaram maior mortalidade, sem diferença significativa quanto ao tempo de hospitalização. Conclusão: Houve alta prevalência da SCR em pacientes com IC crônica descompensada, associada à maior mortalidade e diversos indicadores clínicos.

Resumen Objetivo: Identificar la prevalencia del síndrome cardiorrenal (SCR) en pacientes con insuficiencia cardíaca (IC) crónica descompensada y su relación con los datos sociodemográficos, clínicos y descubiertos en la admisión, la mortalidad y el tiempo de hospitalización. Métodos: Estudio transversal, con enfoque cuantitativo. La muestra estuvo compuesta por 379 historias clínicas de pacientes adultos con diagnóstico médico de IC crónica descompensada, ingresados en hospital público en el estado de São Paulo, durante 2015. La recolección de datos se realizó en 2016. La disfunción renal fue considerada en pacientes con diagnóstico previo de enfermedad renal crónica (ERC) por el índice de filtración glomerular (IFG) < 89 mL/min/1.73 m2. Pruebas con un valor de p menor o igual a 0,05 fueron estadísticamente significativos. Resultados: La prevalencia del SCR fue del 54,1 %, del cual el 24,8 % fue de tipo 1 y el 29,3 % de tipo 2. Los principales factores asociados al SCR fueron: mayor promedio de edad, mujeres, IC de etiología isquémica, menor fracción de eyección, portadores de diabetes mellitus, enfermedad arterial coronaria, uso de estimuladores cardíacos artificiales, hipotiroidismo y enfermedad de Chagas, así como también el perfil hemodinámico de descompensación de la IC en el tipo C y L. Además, se destacan la inapetencia, somnolencia, estertores en la auscultación pulmonar, alteración en la perfusión tisular, reducción del flujo urinario, con aumento del nivel en sangre de potasio, urea y creatinina en la evaluación clínica inicial. Los pacientes con disfunción renal presentaron mayor mortalidad, sin diferencia significativa con relación al tiempo de hospitalización. Conclusión: Se observó una alta prevalencia del SCR en pacientes con IC crónica descompensada, relacionada con una mayor mortalidad y diversos indicadores clínicos.

Abstract Objective: to identify cardiorenal syndrome (CRS) prevalence in patients with decompensated chronic heart failure (HF) and its association with sociodemographic and clinical data, admission findings, mortality and length of hospital stay. Methods: a cross-sectional study with a quantitative approach. The sample consisted of 379 medical records of adult patients with a medical diagnosis of decompensated chronic HF admitted to a public hospital in the state of São Paulo, throughout 2015. Data collection occurred in 2016. Kidney failure was considered in patients with a previous diagnosis of chronic kidney disease (CKD) by glomerular filtration rate (GFR) <89 mL/min/1.73 m2. Tests with a p value less than or equal to 0.05 were statistically significant. Results: CRS prevalence was 54.1%, with 24.8% being type 1 and 29.3% being type 2. The main factors associated with CRS were: higher mean age; women; HF of ischemic etiology; lower ejection fraction; people with diabetes mellitus; coronary artery disease; artificial cardiac stimulator use; hypothyroidism and Chagas disease; hemodynamic profile of HF decompensation in types C and L. Also noteworthy are inappetence, drowsiness, rales on respiratory auscultation, alteration in tissue perfusion, decreased urine output, with increased serum levels of potassium, urea and creatinine in the initial clinical assessment. Patients with kidney failure had higher mortality, with no significant difference in length of hospital stay. Conclusion: There was a high prevalence of CRS in patients with decompensated chronic HF, associated with higher mortality and several clinical indicators.

Cardiorenal syndrome

To maintain homeostasis of the cardiovascular system, the heart and kidney act bidirectionally. Therefore, acute or chronic dysfunction of one organ can cause dysfunction in the other. This phenomenon is characterized as cardiorenal syndrome (CRS). Concurrent dysfunction of the heart and kidney adversely affects one another and eventually worsens patient outcomes through a vicious cycle. Although a CRS classification system has been proposed, the underlying pathophysiology is multifactorial and clinical access continues to be difficult. Although several therapies, including agents that target the renin-angiotensin-aldosterone system, have been utilized, there is not enough evidence to demonstrate their effectiveness for CRS. Thus, more effort should be made to optimize the diagnosis and treatment strategies for CRS patients. This review will introduce CRS as it is currently understood, discuss the pathophysiology, and examine management strategies.

Effect of xinmailong injection on NGAL, hs-cTnT and RAAS in elderly patients with type 2 cardio-renal syndrome / 实用医学杂志

Objective Observation of the effects of Xinmailong injection on NGAL, hs-cTnT and RAAS in elderly patients with type 2 cardio-renal syndrome (CRS) , and EvaluatIon of the clinical efficacy and safety.Methods A total of 86 elderly patients who were collected from November 2015 to February 2017 were diagnosed as type 2 CRS in our department of geriatrics. According to the random number table method, they were randomly divided into two groups. Control group (43 cases) were treated with conventional medical therapy and xinmailong group (43 cases) were treated with xinmailong injection with a dose of 5 mg/kg twice a day for 15 days. The value of sneutrophil gelatin-associated apolipoprotein (NGAL) , hypersensitive troponin T (hs-cTnT) , brain natriuretic peptide (BNP) , plasma renin activity (PRA) , and angiotensin Ⅱ (Ang Ⅱ) , aldosterone (ALD) , left ventricular ejection fraction (LVEF) , six-minute walking test and other indicators were measured before and after treatment. Results After treatment, the value of NGAL, hs-cTnT, BNP, PRA, AngⅡ and ALD decreased in both groups, the value of LVEF and six-minute walking distance increased compared with those before treatment (P <0.05); The above indicators in the xinmailong group experienced a more significant alteration than in control group in the same period (P < 0.05); no side effect occurred in both two groups during the experiment. Conclusion Xinmailong injection can reduce the levels of NGAL, hs-cTnT and BNP in elderly patients with type 2 cardio-renal syndrome, improve heart and kidney function, and have curative positive effect and good safety. This study underlined the mechanism of Xinmailong injection may be related to the inhibition of RAAS activity.

Función renal en pacientes ambulatorios con insuficiencia cardíaca con fracción de eyección reducida; análisis de su evolución e implicancia pronóstica. Seguimiento a 4 años en una Unidad Multidisciplinaria de Insuficiencia Cardíaca / Renal function in outpatients with heart failure with reduced ejection fraction; analysis of its evolution and forecast implications. A 4 year follow up in a Multidisciplinary Unit of Heart Failure / Função renal em pacientes ambulatoriais com insuficiência cardíaca com fração de ejeção reduzida; análise de sua evolução e implicações prognósticas. Acompanhamento de até 4 anos em uma Unidade Multidisciplinar de Insuficiência Cardíaca

Resumen: Introducción: El deterioro de la función renal está asociado a un aumento de la mortalidad en los pacientes con insuficiencia cardíaca (IC). El objetivo de este estudio fue evaluar si la progresión de la enfermedad renal en pacientes estables portadores de IC con fracción de eyección reducida (ICFEr) y enfermedad renal crónica (ERC) se asocia a eventos cardiovasculares (ECV), hospitalización por IC y muerte. Metodología: Estudio de cohorte de seguimiento a 4 años, con análisis en dos etapas: tiempo 1 (inicio del estudio); y tiempo 2 (fin del estudio o muerte). Se definió ICFEr estable como IC con una fracción de eyección del ventrículo izquierdo (FEVI)<40% sin elementos de descompensación. Se definió ERC con la presencia de un filtrado glomerular estimado (FGe) < 60 ml/min/1,73 y ERC estable en ausencia de fracaso renal agudo. Resultados: Se incluyeron 94 pacientes con media de seguimiento de 37,2 meses; la edad media fue 69,5 años, 71.3% de sexo masculino. La cardiomiopatía era isquémica en 48% y la nefropatía vascular fue la predominante (62%). Se diagnosticó síndrome cardio-renal tipo 2 en 76 (81%) pacientes. Se evidenció descenso significativo del FGe entre los tiempos de análisis (tiempo 1: 45 ± 10 ml/min.; tiempo 2: 38 ± 15 ml/min.; p < 0,001) y 50% de los pacientes tuvieron peoría del estadio de ERC (p = 0,027). Se halló asociación entre progresión de la ERC con mayor frecuencia de ECV (P=0,002), ingresos por IC (OR 3,3;IC95% 1,9-11,2; p = 0.044) y muerte cardiovascular (OR 10,9;IC95% 2,9-40,1; p < 0.001). Conclusiones: La progresión de la ERC en pacientes con ICFEr ambulatorios se asocia a un peor pronóstico en términos de mortalidad cardiovascular, ingresos por IC y ECV.

Abstract: Introduction: Deterioration of renal function is associated with increased mortality in patients with heart failure (HF). The objective of the present study was to assess whether the progression of kidney disease is associated with the appearance of cardiovascular events (CVE), hospitalization for HF and death in a cohort of stable outpatients with chronic kidney disease (CKD) and Heart failure with reduced ejection fraction (HFrEF). Methodology: A 4 years follow-up cohort study, with a two stage analysis: time 1 (start of the study); and time 2 (end of study or death). Stable HFrEF was defined as HF with an ejection fraction of the left ventricle (LVEF)<40% without elements of decompensation. An estimated glomerular filtration less than 60 ml / min / 1.73 was used as diagnostic criterion for CKD and stable CKD in the absence of acute renal failure. Results: A total of 94 patients were included with a follow up mean of 37.2 months; the mean age was 69.5 years ± 9 years, 71.3% were male. Cardiomyopathy was ischemic in 48% and vascular nephropathy was predominant (62%). Cardio-renal syndrome type 2 was diagnosed in 76 (81%) patients. There was a significant decrease in eGFR between the time of analysis (time 1: 45 ± 10 ml/min, time 2: 38 ± 15 ml/min, p <0.001) and 50% of patients worsened their stage of CKD (p = 0.027). An association was found between progression of CKD with a higher frequency of CVD (P = 0.002), hospitalization for HF (OR 3.3, 95% CI 1.9-11.2, p = 0.044) and cardiovascular death (OR 10.9, 95% CI 2.9-40.1, p <0.001). Conclusions: The progression of CKD is associated with a worse prognosis in not hospitalized HF patients in terms of cardiovascular mortality, admissions for HF and CVE.

Resumo: Introdução: A deterioração da função renal está associada ao aumento da mortalidade em pacientes com insuficiência cardíaca (IC). O objectivo deste estudo foi avaliar se a progressão da doença renal em pacientes com IC estáveis ​​com fracção de ejecção reduzida (ICFER) e doença renal crónica (IRC) está associada com eventos cardiovasculares (DCV), HF hospitalização e morte. Metodologia: Estudo de coorte de acompanhamento aos 4 anos, com análise em duas etapas: tempo 1 (início do estudo); e tempo 2 (fim do estudo ou morte). O rEFFE estável foi definido como IC com fração de ejeção do ventrículo esquerdo (FEVE) <40% sem elementos de descompensação. DRC foi definida na presença de uma taxa de filtração glomerular estimada (EGFR) <60 ml / min / 1,73 CEI e estável na ausência de insuficiência renal aguda. Resultados: Foram incluídos 94 pacientes com seguimento médio de 37,2 meses; a idade média foi de 69,5 anos, 71,3% do sexo masculino. A cardiomiopatia era isquêmica em 48% e a nefropatia vascular era predominante (62%). Síndrome Cardio-renal tipo 2 foi diagnosticada em 76 (81%) pacientes. diminuição significativa da taxa de filtração glomerular entre os tempos de verificação (45 ± 10 ml / min; cerca de 2 cerca de 1 38 ± 15 ml / min; p <0,001) foi evidenciado e 50% dos pacientes tiveram a fase de Peoria DRC (p = 0,027). e morte cardiovascular (OU 10,9 associação entre a progressão DRC de DCV com maior frequência (P = 0,002), o rendimento de IC (OR 3.3, 95 % CI 1.9-11.2 p = 0,044), verificou-se IC 95% 2,9-40,1, p <0,001). Conclusões: A progressão da DRC em pacientes com HFrR ambulatorial está associada a um pior prognóstico em termos de mortalidade cardiovascular, IC e DCV

Biomarkers of cardio-renal syndrome in uremic myocardiopathy animal model / Biomarcadores de síndrome cardiorrenal em modelo animal de miocardiopatia urêmica

ABSTRACT Introduction: Cardio-renal syndrome subtype 4 (CRS4) is a condition of primary chronic kidney disease that leads to reduction of cardiac function, ventricular hypertrophy, and risk of cardiovascular events. Objective: Our aim was to understand the mechanisms involved on the onset of CRS4. Methods: We used the nephrectomy 5/6 (CKD) animal model and compared to control (SHAM). Serum biomarkers were analyzed at baseline, 4, and 8 weeks. After euthanasia, histology and immunohistochemistry were performed in the myocardium. Results: Troponin I (TnI) was increased at 4 weeks (W) and 8W, but nt-proBNP showed no difference. The greater diameter of cardiomyocytes indicated left ventricular hypertrophy and the highest levels of TNF-α were found at 4W declining in 8W while fibrosis was more intense in 8W. Angiotensin expression showed an increase at 8W. Conclusions: TnI seems to reflect cardiac injury as a consequence of the CKD however nt-proBNP did not change because it reflects stretching. TNF-α characterized an inflammatory peak and fibrosis increased over time in a process connecting heart and kidneys. The angiotensin showed increased activity of the renin-angiotensin axis and corroborates the hypothesis that the inflammatory process and its involvement with CRS4. Therefore, this animal study reinforces the need for renin-angiotensin blockade strategies and the control of CKD to avoid the development of CRS4.

RESUMO Introdução: A síndrome cardiorrenal (SCR) tipo 4 é uma afecção da doença renal crônica primária que leva a redução da função cardíaca, hipertrofia ventricular e risco de eventos cardiovasculares. Objetivo: O objetivo do presente estudo foi compreender os mecanismos envolvidos no surgimento da SCR tipo 4. Métodos: Um modelo animal de nefrectomia 5/6 (DRC) foi comparado a animais de controle (Placebo). Biomarcadores séricos foram analisados no início do estudo e com quatro e oito semanas de estudo. Após eutanásia, foram realizados exames histológicos e de imunoistoquímica no tecido miocárdico. Resultados: Troponina I (TnI) estava aumentada nas semanas quatro (S4) e oito (S8), mas o NT-proBNP não apresentou diferenças. O diâmetro maior dos cardiomiócitos indicava hipertrofia ventricular esquerda. Os níveis mais elevados de TNF-α foram identificados na S4 com redução na S8, enquanto fibrose foi mais intensa na S8. A expressão de angiotensina mostrou elevação na S8. Conclusões: TnI parece sugerir lesões cardíacas em consequência da DRC, porém o NT-proBNP não sofreu alterações por refletir alongamento. O TNF-α evidenciou um pico inflamatório e a fibrose aumentou ao longo do tempo devido ao processo de conexão entre rins e coração. A angiotensina mostrou aumento da atividade do eixo renina-angiotensina, corroborando a hipótese do processo inflamatório e seu envolvimento com SCR tipo 4. Portanto, o presente estudo em modelo animal reforça a necessidade de em adotar estratégias com bloqueadores de renina-angiotensina e controle da DRC para evitar o desenvolvimento de SCR tipo 4.

Síndrome cardiorrenal. Una revisión / Cardio-renal syndrome. A review

La presente revisión analiza los síndromes cardiorrenales tipo 1 y 2, que se desarrollan a partir de la afectación cardíaca, siendo el compromiso renal consecuencia de la misma, destacando la profunda interacción entre ambos órganos. Se estudian la epidemiología, la fisiopatología, los aspectos diagnósticos y los pilares del tratamiento de cada uno de ellos, considerando los diferentes ensayos clínicos que aportan la evidencia fundamental para el manejo de los pacientes. Se destacan los diversos factores involucrados en su génesis: hemodinámicos, inflamatorios, neurohumorales, iatrogénicos. Se aborda el cuestionamiento de su existencia como una entidad real, tal como se define y estudia actualmente, quedando planteada la necesidad de progresar en el conocimiento de sus aspectos diagnósticos y terapéuticos. Se destaca finalmente la importancia de desarrollar medidas preventivas del daño que pueda provocar un órgano sobre el otro y de los demás factores involucrados.

This review analyzes the cardio-renal syndromes type 1 and 2, which develop from cardiac involvement with renal involvement being a consequence of it, highlighting the strong interaction between both organs. The epidemiology, the pathophysiology, the diagnostic aspects, and the pillars of the treatment of each of them are studied, considering the different clinical trials that provide the evidence for their management. It highlights the various factors involved in its genesis: hemodynamic, inflammatory, neurohumoral and iatrogenic. The controversy of its existence as a real entity, as it is currently defined and studied, is addressed, and the need to progress in the knowledge of its diagnostic and therapeutic aspects is raised. Finally, the importance of developing preventive measures of damage that one organ may cause over the other and of the other involved factors, is highlighted.

Factores asociados con lesión renal aguda en pacientes hospitalizados con diagnóstico de insuficiencia cardiaca agudizada / Risk factors associated with acute kidney injury in hospitalized patients with acute heart failure

Resumen ANTECEDENTES: La lesión renal aguda constituye una complicación frecuente en los pacientes con insuficiencia cardiaca aguda. OBJETIVO: Describir las características clínicas, epidemiológicas y de laboratorio de los pacientes hospitalizados por un episodio de síndrome cardiorrenal tipo 1. MATERIAL Y MÉTODO: Estudio prospectivo que incluyó pacientes hospitalizados por un episodio de insuficiencia cardiaca aguda, cuyo diagnóstico clínico se estableció con los criterios de Framingham y se corroboró por ecocardiografía y concentraciones séricas del péptido natriurético cerebral. La lesión renal aguda se diagnosticó y clasificó al ingreso o durante la hospitalización según criterios del Acute Kidney Injury Network (AKIN). Se compararon las características clínicas, epidemiológicas y de laboratorio entre pacientes con y sin lesión renal aguda. Los factores de riesgo asociados con lesión renal aguda se estudiaron con regresión logística. RESULTADOS: Se incluyeron 67 pacientes; la edad promedio fue de 66 ± 16 años y 52.2% eran del sexo masculino. La lesión renal aguda se observó en 53.7% de los pacientes de los que 47.2% correspondieron a episodios de AKIN 1, 27.8% a AKIN 2 y 25% a AKIN 3. El 13.9% de los episodios de lesión renal aguda requirió diálisis y 50% de los pacientes con lesión renal aguda tuvo recuperación de la función renal a su egreso. Los factores de riesgo asociados con lesión renal aguda fueron: administración de inotrópico con OR (razón de momios) de 5.0 (IC95% 0.98-26.6; p = 0.05) y el diagnóstico previo de enfermedad renal crónica con OR de 18 (IC95% 3.6-102.2; p < 0.01). CONCLUSIONES: La lesión renal aguda fue una complicación frecuente en los pacientes hospitalizados por insuficiencia cardiaca aguda en nuestra población. El requerimiento de inotrópico, como expresión de la gravedad de la insuficiencia cardiaca y el antecedente de enfermedad renal crónica fueron los factores independientemente asociados con la aparición de lesión renal aguda.

Abstract BACKGROUND: Acute kidney injury is a common complication in patients with acute heart failure. OBJECTIVE: To describe the clinical, epidemiological and laboratory characteristics of patients hospitalized due to an event of type 1 cardiorrenal syndrome. MATERIAL AND METHOD: A prospective study including patients hospitalized with acute heart failure, whose clinical diagnosis was established according to Framingham criteria. Definitive diagnosis was corroborated by echocardiography and serum levels of brain natriuretic peptide. Acute kidney injury was diagnosed and classified at admission or during hospitalization according to Acute Kidney Injury Network (AKIN). Clinical, epidemiological and laboratorial characteristics were compared between patients with and without acute kidney injury. Etiology, severity and evolution of acute kidney injury episodes were studied. The risk factors associated to acute kidney injury were studied with logistic regression analysis. RESULTS: There were included 67 patients with mean age of 66 ± 16 years and 52.2% were male. Acute kidney injury was observed in 53.7% of the patients, of whom 47.2% corresponded to episodes of AKIN 1, 27.8% to AKIN 2 and 25% to AKIN 3. Oliguric acute kidney injury was present in 33.3% of cases and 13.9% required dialysis. Renal function recovery at hospital discharge was observed in 50% of patients. The risk factors associated with acute kidney injury were: inotropic use with OR of 5.0 (95% CI 0.98-26.6, p = 0.05) and previous diagnosis of chronic renal disease with OR of 18 (95% CI, 3.6-102.2; p < 0.01). CONCLUSIONS: Acute kidney injury was a frequent complication in patients hospitalized for acute heart failure in our population. Inotropic requirement as an expression of the severity of heart failure and a history of chronic renal disease were the independently factors associated with the development of acute kidney injury.

Clinical features and outcomes of patients with the cardio-renal syndrome admitting to a surgical intensive care unit / 中华危重病急救医学

Objective To investigate the clinical features and risk factors on outcomes of patients with cardio-renal syndrome (CRS) in surgical intensive care unit (SICU). Methods The clinical data of the patients admitted to SICU of Peking University People's Hospital from January 1st 2017 to December 31st 2017 were analyzed retrospectively, including gender, age, severity of the disease, underlying diseases, type of CRS, precipitating factors of CRS, cardiac and renal function [cardiac troponin I (cTnI), B-type natriuretic peptide (BNP), serum creatinine (SCr), glomerular filtration rate (eGFR)], outcomes [secondary outcomes, duration of mechanical ventilation, the length of ICU stay, the length of hospital stay, 28-day mortality and hospital mortality]. Patients were grouped according to CRS classification or hospitalization prognosis, the clinical features within different CRS types were analyzed, and risk factors on outcomes of the CRS patients were analysed by Logistic regression. Results 86 (7.3%) of the 1 172 patients during the study period had CRS. ①CRS clinical features: CRS 1-5 type patients accounted for 24.4% (21 cases), 1.2% (1 case), 20.9% (18 cases), 1.2% (1 case) and 52.3% (45 cases) respectively, CRS type 1, 3 and 5 were the main types (i.e. acute cardiac and renal dysfunction), while type 5 CRS was the highest (i.e. organ dysfunction caused by simultaneous involvement of cardiac and renal functions secondary to systemic diseases was the most common). Baseline BNP (Z = 11.365, P =0.023), SCr peak (Z = 13.405, P = 0.009) and baseline eGFR (F = 2.648, P = 0.037) were significantly different within the CRS 5 types. The basic cardiac function of type 1 CRS patients was significantly worse than that of type 3 and type 5 CRS patients [baseline BNP (μg/L): 434.2 (187.0, 1 252.0) vs. 154.9 (66.4, 272.5), 268.5 (124.1, 486.6), both P <0.05]. The basic renal function of type 3 CRS patients was significantly worse than that of type 5 CRS patients [baseline eGFR (mL/min): 71.0±30.3 vs. 88.3±29.0, P < 0.05]. The severity of acute kidney injury (AKI) in type 3 CRS patients was significantly higher than that in type 1 and type 5 CRS patients [SCr peak (μmol/L): 285.0 (171.5, 420.6) vs. 143.0 (99.5, 213.5), 189.0 (105.5, 280.5), both P < 0.01]. There were no significant differences in gender, age, department, acute physiology and chronic health evaluationⅡ (APACHEⅡ), intraoperative blood loss, basic cTnI and SCr levels, BNP peak, AKI staging and prognostic indicators among patients with various types of CRS. ② Death risk analysis:43 (50%) of the 86 CRS patients died during the hospital stay. Compared with the survival patients, CRS death patients were older [years old: 72 (57, 80) vs. 62 (50, 73)] and had higher APACHEⅡ score [22 (17, 29) vs. 18 (15, 21)], with higher proportion of cerebrovascular disease (9.3% vs. 0). Regarding to precipitating factors of CRS, sepsis/septic shock (41.9% vs. 18.6%) and surgery stress (9.3% vs. 0) were remarkably increased in death patients. Death patients had higher cTnI and SCr peak [cTnI peak (μg/L): 1.155 (0.192, 5.125) vs. 0.122 (0.045, 0.610), SCr peak (μmol/L): 208 (143, 295) vs. 146 (101, 289)] and also high proportion of AKI stage 3 (41.9% vs. 20.9%), higher rate of secondary infection (67.4% vs. 30.2%), prolonged duration of mechanical ventilation and the length of ICU stay [hours: 179 (61, 470) vs. 37 (7, 134);days: 10 (4, 24) vs. 5 (2, 11)], with statistically significant differences (all P < 0.05). Logistic regression analysis showed that the elderly [odds ratio (OR) = 1.053, 95% confidence interval (95%CI) = 1.003-1.094, P = 0.010], high APACHE Ⅱscore (OR = 1.165, 95%CI = 1.057-1.285, P = 0.002), sepsis/septic shock (OR = 4.561, 95%CI = 1.351-15.391, P = 0.014) and AKI stage 3 (OR = 5.468, 95%CI = 1.457-20.530, P = 0.012) were independent risk factors for hospital death in CRS patients. Conclusions Surgical ICU patients with CRS are characterized by acute cardiac and renal dysfunction. CRS type 5 is the most common and has a high fatality rate. Age, severity of illness, sepsis/septic shock and AKI stage 3 are independent risk factors of death.

Altered Nitric Oxide System in Cardiovascular and Renal Diseases / 전남의대학술지

Nitric oxide (NO) is synthesized by a family of NO synthases (NOS), including neuronal, inducible, and endothelial NOS (n/i/eNOS). NO-mediated effects can be beneficial or harmful depending on the specific risk factors affecting the disease. In hypertension, the vascular relaxation response to acetylcholine is blunted, and that to direct NO donors is maintained. A reduction in the activity of eNOS is mainly responsible for the elevation of blood pressure, and an abnormal expression of iNOS is likely to be related to the progression of vascular dysfunction. While eNOS/nNOS-derived NO is protective against the development of atherosclerosis, iNOS-derived NO may be proatherogenic. eNOS-derived NO may prevent the progression of myocardial infarction. Myocardial ischemia/reperfusion injury is significantly enhanced in eNOS-deficient animals. An important component of heart failure is the loss of coronary vascular eNOS activity. A pressure-overload may cause severer left ventricular hypertrophy and dysfunction in eNOS null mice than in wild-type mice. iNOS-derived NO has detrimental effects on the myocardium. NO plays an important role in regulating the angiogenesis and slowing the interstitial fibrosis of the obstructed kidney. In unilateral ureteral obstruction, the expression of eNOS was decreased in the affected kidney. In triply n/i/eNOS null mice, nephrogenic diabetes insipidus developed along with reduced aquaporin-2 abundance. In chronic kidney disease model of subtotal-nephrectomized rats, treatment with NOS inhibitors decreased systemic NO production and induced left ventricular systolic dysfunction (renocardiac syndrome).

Altered Nitric Oxide System in Cardiovascular and Renal Diseases / 전남의대학술지

Nitric oxide (NO) is synthesized by a family of NO synthases (NOS), including neuronal, inducible, and endothelial NOS (n/i/eNOS). NO-mediated effects can be beneficial or harmful depending on the specific risk factors affecting the disease. In hypertension, the vascular relaxation response to acetylcholine is blunted, and that to direct NO donors is maintained. A reduction in the activity of eNOS is mainly responsible for the elevation of blood pressure, and an abnormal expression of iNOS is likely to be related to the progression of vascular dysfunction. While eNOS/nNOS-derived NO is protective against the development of atherosclerosis, iNOS-derived NO may be proatherogenic. eNOS-derived NO may prevent the progression of myocardial infarction. Myocardial ischemia/reperfusion injury is significantly enhanced in eNOS-deficient animals. An important component of heart failure is the loss of coronary vascular eNOS activity. A pressure-overload may cause severer left ventricular hypertrophy and dysfunction in eNOS null mice than in wild-type mice. iNOS-derived NO has detrimental effects on the myocardium. NO plays an important role in regulating the angiogenesis and slowing the interstitial fibrosis of the obstructed kidney. In unilateral ureteral obstruction, the expression of eNOS was decreased in the affected kidney. In triply n/i/eNOS null mice, nephrogenic diabetes insipidus developed along with reduced aquaporin-2 abundance. In chronic kidney disease model of subtotal-nephrectomized rats, treatment with NOS inhibitors decreased systemic NO production and induced left ventricular systolic dysfunction (renocardiac syndrome).

Cardiorenal Syndrome / 대한내과학회지

Although combined cardiac and renal dysfunction is common in hospitalized patients and portends a poor prognosis, lack of understanding of the pathogenesis and classification of the condition has hampered the development of therapeutic strategies. Interactions between the heart and kidney involve multiple hemodynamic and nonhemodynamic factors and are usually bidirectional, as acute or chronic dysfunction of the cardiac or renal systems can negatively affect one another. This review introduces a new definition and classification system of cardiorenal syndrome advocated by a consensus conference of the Acute Dialysis Quality Initiative and summarizes the current understanding of cardiorenal syndrome.

Síndrome cardiorrenal tipo 1 en la unidad de cuidados intensivos coronarios del Hospital Nacional Arzobispo Loayza / Cardiorenal syndrome type 1 in the intensive coronary care unit of the Hospital Nacional Arzobispo Loayza

Objetivos: Evaluar la incidencia de síndrome cardiorrenal tipo 1 (SCR1) en una unidad de cuidados intensivos coronarios y su asociación a mortalidad intrahospitalaria a 30 días, así como a otras características epidemiológicas. Métodos: Se revisaron las historias clínicas de todos los pacientes hospitalizados con diagnóstico de falla cardíaca aguda en un periodo de 4 años. Se definió como SCR1 la presencia de falla cardíaca aguda más una creatinina al ingreso ≥ 0.3 mg/dL con respecto a la creatinina basal calculada por la fórmula MDRD75, y/o una elevación ≥ 50% de la creatinina al ingreso en un periodo de 48 h. Resultados: La incidencia de SCR1 fue del 27.87%, IC95%: 20.13-36.71 (34 de 122). Hubo una mayor frecuencia de SCR1 en los pacientes que ingresaron con diagnóstico de shock cardiogénico (RR: 2.02; IC95%: 1.20-3.93; p = 0.0378) y en los que tenían niveles más altos de hemoglobina (p = 0.0412). El SCR1 se asoció a una mayor mortalidad intrahospitalaria a 30 días (HR: 4.11; IC95%: 1.20-14.09; p = 0.0244). Conclusiones: La incidencia de SCR1 en la unidad de cuidados intensivos coronarios encontrada en nuestro estudio es similar a la descrita en estudios extranjeros. La presencia de shock cardiogénico como causa de falla cardíaca y valores más altos de hemoglobina se asociaron a una mayor incidencia de SCR1. Los pacientes con SCR1 tuvieron mayor mortalidad intrahospitalaria a 30 días.

Objectives: This study sought to evaluate the incidence of cardiorenal syndrome (CRS) type 1 in a coronary care unit and its association with hospital mortality within 30 days of admission, as well as other epidemiological characteristics. Methods: The medical records of all the patients who were hospitalized with the diagnosis of acute heart failure in a 4-year period were reviewed. CRS type 1 was characterized by the presence of acute heart failure and an elevation of serum creatinine ≥ 0.3 mg/dL in comparison to the baseline creatinine calculated by the MDRD75 equation and/or the elevation of ≥ 50% of the admission serum creatinine within a 48 h period. Results: The incidence of CRS type 1 was 27.87%, 95% CI: 20.13-36.71 (34 of 122). There was a higher frequency of CRS type 1 in those patients who were admitted with the diagnosis of cardiogenic shock (adjusted RR 2.02, 95% CI: 1.20-3.93, p = 0.0378) and in those with higher hemoglobin levels (p = 0.0412). The CRS type 1 was associated with an increase of 30-day mortality (HR: 4.11, 95% CI: 1.20-14.09, p = 0.0244). Conclusions: The incidence of CRS type 1 in the coronary care unit found in our study is similar to those found in foreign studies. The history of stroke and the higher values of hemoglobin were associated with a higher incidence of cardiorenal syndrome type 1. Patients with CRS type 1 had a higher hospital mortality within 30 days of admission.

Biomarkers in Cardiology - Part 2: In Coronary Heart Disease, Valve Disease and Special Situations / Biomarcadores em Cardiologia - Parte 2: Na Doença Coronária, Doença Valvar e Situações Especiais

Cardiovascular diseases are the main causes of mortality and morbidity in Brazil. Their primary and secondary preventions are a priority for the health system and require multiple approaches for increased effectiveness. Biomarkers are tools used to identify with greater accuracy high-risk individuals, establish a faster diagnosis, guide treatment, and determine prognosis. This review aims to highlight the importance of biomarkers in clinical cardiology practice and raise relevant points regarding their application and perspectives for the next few years. This document was divided into two parts. This second part addresses the application of biomarkers in coronary heart disease, valvular diseases, cardio-oncology, pulmonary embolism, and cardiorenal syndrome.

Doenças cardiovasculares são as principais causas de mortalidade e morbidade no Brasil. As prevenções primária e secundária dessas doenças são prioritárias para o sistema de saúde e requerem múltiplas abordagens para aumentar sua eficácia. Os biomarcadores são ferramentas utilizadas para identificar com mais precisão indivíduos de alto risco, diagnosticar com mais rapidez, assim como auxiliar no tratamento e na determinação do prognóstico. Esta revisão teve por objetivo ressaltar a importância dos biomarcadores na prática clínica da cardiologia, assim como levantar os pontos relevantes de sua utilização e o que há de promissor para os próximos anos. Nesse sentido, este documento foi dividido em duas partes. Esta segunda parte aborda a utilização dos biomarcadores na doença coronariana, nas doenças valvares, na cardio-oncologia, na embolia pulmonar e na síndrome cardiorrenal.

Establishment of Cardio-renal Syndrome and the mRNA Expression of Pro-renin Receptor in Experimental Rat’s Model / 中国循环杂志

Objective: To establish the cardio-renal syndrome (CRS) model by coarctation of abdominal aorta (CAA) with renal ischemia reperfusion injury (RIRI), and to observe the mRNA expression of pro-renin receptor [(P)RR] in experimental rats. Methods: A total of 42 Wistar rats were randomly divided into 4 groups: Sham group, CAA group, RIRI group and CAA+RIRI group.n=10 in each group, 2 rats died during the modeling and all animals were treated for 16 weeks. Blood levels of BNP, creatinine (Cr), urea nitrogen (BUN), the activity of rennin, the contents of angiotensin-I (AT-I), AT-II and aldosterone were examined by laboratory test. The diastolic end inter-ventricular septum thickness (DEIVST), DELVPT, LVEF, ventricular weight index (VWI) and cardiac weight index were detected by small animal echocardiography. The histological changes of myocardium and kidney tissue were measured by HE staining, and the mRNA expressions of pro-renin receptor in myocardium and kidney tissues were measured by RT-PCR. Results: Compared with Sham group, blood levels of BNP were increased in the other 3 groups,P0.05. Compared with CAA group, CAA+RIRI group had more obvious changes of DEIVST and LVEF,P<0.01. Compared with RIRI group, CAA+RIRI group had more obvious ventricular hypertrophy, higher VWI and cardiac weight index, allP<0.05. HE staining presented that CAA+RIRI group had broadening of myocardial cell bundle space, decreased left renal index, severe tubular atrophy and partial glomerular atrophy. RT-PCR demonstrated that compared with Sham group, the mRNA expressions of pro-renin receptor in myocardium and kidney tissues were decreased in the other 3 groups. Conclusion: Combined CAA+RIRI method may damage the cardial and renal tissues at the same time which was more severe than either CAA or RIRI. While CAA+RIRI model has better controllability and higher consistency that provides a methodological reference for pro-renin receptor in treating CRS in experimental rat’s model.

Therapeutic effect of continuous renal replacement therapy on different types of cardiorenal syndrome / 心血管康复医学杂志

Objective:To observe therapeutic effect of continuous renal replacement therapy (CRRT ) on different types of cardiorenal syndrome (CRS) .Methods :According to patient′s conclition ,a total of 247 CRS patients were divided into type 1 group (n=47) ,type 2 group (n=51) ,type 3 group (n=55) ,type 4 group (n=49) and type 5 group (n=45) .All patients received CRRT ,echocardiography and plasma level of N terminal pro B type natriuretic peptide (NT‐proBNP) detect to evaluate cardiac function status ;the 24h urine volume and endogenous creatinine clearance rate (Ccr) were measured to assess renal function status before and after treatment . Results:Compared with before treatment ,on one week after CRRT ,LVEF ,urine volume and Ccr level significantly rose ,NT‐proBNP level significantly reduced ( P<0.05 or <0.01) .Compared with type 4 and 5 group ,there were significant rise in LVEF [ (48.98 ± 1.55)% ,(44.67 ± 1.48)% vs .(55.13 ± 4.27)% ,(53.73 ± 3.52)% ,(57.95 ± 2.89)% ] ,urine volume [ (1118.83 ± 168.09 ) ml , (1125.47 ± 177.28 ) ml vs . (1655.67 ± 198.37 ) ml , (1697.47 ± 171.27 ) ml , (1702.72 ± 179.28) ml] and Ccr level [ (40.11 ± 1.79) ,(41.11 ± 1.39) vs .(52.33 ± 2.49) ,(50.97 ± 2.11) , (51.32 ± 2.01 )] , and significant reduction in NT‐proBNP level [ (3738.19 ± 118.77 ) , (3378.38 ± 121.82 ) vs . (2137.51 ± 123.59) ,(2421.12 ± 121.22) ,(2139.81 ± 147.28)] in type 1 ,2 and 3 group ,P<0.05 all .Conclusion:CRRT is effective on different types of CRS ,but it′s best on type 1~3 than those of type 4~5 , which may be re‐lated to different pathological mechanisms of CRS different types .